Learn more about how our research and work with health care stakeholders drove health policy conversations forward last year.
Who pays now, and who benefits later?
How can we address health coverage challenges?
How is high-quality, real-world evidence being generated, accepted and used to inform decision-making?
Is the value of medicines being recognized as an integral component of care?
What can we do to ensure patients have meaningful access to appropriate medications?
How can the health care system support biopharmaceutical innovation that improves patients’ lives?
New research from Tufts Medical Center and the National Pharmaceutical Council indicates that patient access to therapies depends on factors other than cost and clinical benefit.
In the March issue of Specialty Pharmacy Times, NPC President Dan Leonard says it’s time to think differently about how we pay for health care and assess value and benefits.
The National Pharmaceutical Council welcomed four companies, AstraZeneca, Gilead Sciences, Horizon Pharma and Spark Therapeutics, as the newest members of the health care research organization.